A Retrospective Single-Center Study of Ferric Derisomaltose in Toddler and School-Age Pediatric Patients.

Several intravenous (IV) iron formulations are used in pediatrics for the treatment of iron deficiency anemia (IDA) and iron deficiency (ID). Ferric derisomaltose (FDI) is a formulation that has not been well studied. This study reports retrospective real-world use and response in young pediatric patients at a single tertiary hospital receiving IV FDI. A total of 11 FDI infusions were administered to pediatric patients ranging from 2 to 10 years of age with isolated ID or IDA. There were zero reactions. Results from our cohort suggest that FDI administration is feasible in this patient population.